Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Status
- RECRUITING
- Phase
- PHASE3
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
- Status
- RECRUITING
- Phase
- PHASE1
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Status
- RECRUITING
- Phase
- PHASE2
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
- Status
- RECRUITING
- Phase
- N/A
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- Status
- RECRUITING
- Phase
- PHASE2
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- NA
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
- Status
- RECRUITING
- Phase
- PHASE3
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
- Status
- WITHDRAWN
- Phase
- PHASE2
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2